Growth Hormone SecretagoguesWADA Prohibited
Sermorelin
Synonyms: GRF 1-29, Geref, Sermorelin Acetate
Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Critical Safety & Regulatory Notice
Sermorelin is classified as a regulated, unapproved, or research-only substance. Doping/Regulatory Status: FDA approved in 1997 under brand Geref (discontinued commercially in 2008). Prohibited by WADA under Section S2.. Clinical safety profiles for human use are deficient or not approved.
History & Discovery Timeline
Sermorelin was synthesized in the 1980s as the functional N-terminal fragment of native human GHRH containing the first 29 amino acids.
What it is: It is a synthetic 29-amino-acid peptide representing the active fragment of GHRH. It falls under the Metabolic category.
Proposed Mechanisms & Research Findings: It binds GHRH receptors in the pituitary gland, stimulating the production and release of endogenous growth hormone in a pulsatile manner.
Regulatory & Safety Status: It was previously FDA approved for growth hormone deficiency, but is now primarily used in compounding and research. Online non-prescription sources carry heavy contamination risks.
Athletic & Anti-Doping Status: Strictly prohibited by WADA under Section S2. Use leads to athletic bans.
Understanding Sermorelin Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:30 Amino Acids
Primary Action & Category:GHRH Receptor Agonist (Growth Hormone Secretagogues)
Primary Receptors:GHRH Receptor (GHRHR)
Figure 1: Detailed molecular mechanism pathways of Sermorelin (click to enlarge).